C16 Lactosylceramide (d18:1/16:0) – 5 mg

Brand:
Cayman
CAS:
4201-62-1
Storage:
-20
UN-No:
Non-Hazardous - /

C16 Lactosylceramide is an endogenous bioactive sphingolipid.{41044} It forms membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs), suggesting a role in cell signaling. Plasma levels of C16 lactosylceramide are elevated in insulin-resistant cattle.{38685} C16 Lactosylceramide is also upregulated in a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder.{40751} [Matreya, LLC. Catalog No. 1532]  

 

Available on backorder

SKU: 24352 - 5 mg Category:

Description

A bioactive sphingolipid; forms membrane microdomains with Lyn kinase and the αi subunits of inhibitory GPCRs; plasma levels are elevated in insulin-resistant cattle; upregulated in a mouse model of Niemann-Pick type C1 disease


Formal name: N-[(1S,2R,3E)-1-[[(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide

Synonyms:  C16 Lactosyl(β) Ceramide (d18:1/16:0)|LacCer(d18:1/16:0)|Lactosylceramide (d18:1/16:0)|N-Hexadecanoyl Lactosylceramide

Molecular weight: 862.2

CAS: 4201-62-1

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Lipid Biochemistry|Sphingolipids||Research Area|Neuroscience|Neurodegenerative Disorders